Neurizon Therapeutics Limited (ASX:NUZ)
Australia · Delayed Price · Currency is AUD 0.0620
-0.0010 (-1.59%)
May 29, 2026, 4:10 PM AEST
Neurizon Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Revenue | - | - | - | - | 3.38 | 2.14 |
Other Revenue | 5.98 | 1.54 | 0.84 | 0.87 | 1.13 | 1.52 |
| 5.98 | 1.54 | 0.84 | 0.87 | 4.51 | 3.66 | |
Revenue Growth (YoY) | 294.48% | 82.70% | -3.66% | -80.63% | 23.33% | -11.24% |
Cost of Revenue | - | - | - | - | 0.31 | 0.23 |
Gross Profit | 5.98 | 1.54 | 0.84 | 0.87 | 4.2 | 3.43 |
Selling, General & Admin | 5.87 | 6.28 | 2.44 | 1.5 | 4.74 | 3.85 |
Research & Development | 14.28 | 11.68 | 3.85 | 1.03 | 0.76 | 0.55 |
Operating Expenses | 20.85 | 18.48 | 6.66 | 2.52 | 5.82 | 4.7 |
Operating Income | -14.87 | -16.94 | -5.82 | -1.65 | -1.62 | -1.27 |
Interest Expense | -0.13 | - | - | - | -0.09 | -0.08 |
Interest & Investment Income | 0.14 | 0.34 | 0.02 | 0.08 | 0 | 0.01 |
EBT Excluding Unusual Items | -14.85 | -16.59 | -5.79 | -1.57 | -1.71 | -1.34 |
Asset Writedown | - | - | -3.11 | - | - | - |
Pretax Income | -14.85 | -16.59 | -8.9 | -1.57 | -1.71 | -1.34 |
Earnings From Continuing Operations | -14.85 | -16.59 | -8.9 | -1.57 | -1.71 | -1.34 |
Earnings From Discontinued Operations | - | - | 1.23 | -4.64 | - | - |
Net Income | -14.85 | -16.59 | -7.67 | -6.21 | -1.71 | -1.34 |
Net Income to Common | -14.85 | -16.59 | -7.67 | -6.21 | -1.71 | -1.34 |
Shares Outstanding (Basic) | 504 | 487 | 371 | 321 | 317 | 316 |
Shares Outstanding (Diluted) | 504 | 487 | 371 | 321 | 317 | 316 |
Shares Change (YoY) | 14.98% | 31.44% | 15.51% | 1.30% | 0.36% | 6.66% |
EPS (Basic) | -0.03 | -0.03 | -0.02 | -0.02 | -0.01 | -0.00 |
EPS (Diluted) | -0.03 | -0.03 | -0.02 | -0.02 | -0.01 | -0.00 |
Free Cash Flow | -17.46 | -14.29 | -5.17 | -1.6 | -1.38 | -1.04 |
Free Cash Flow Per Share | -0.04 | -0.03 | -0.01 | -0.01 | -0.00 | -0.00 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 93.03% | 93.84% |
Operating Margin | -248.65% | -1101.41% | -691.08% | -188.64% | -35.92% | -34.81% |
Profit Margin | -248.37% | -1079.02% | -911.61% | -710.99% | -37.88% | -36.57% |
Free Cash Flow Margin | -291.97% | -929.50% | -614.05% | -183.02% | -30.50% | -28.43% |
EBITDA | -14.87 | -16.94 | -5.82 | -1.32 | -1.45 | -1.11 |
EBITDA Margin | -248.65% | - | - | -151.27% | -32.22% | -30.33% |
D&A For EBITDA | -0 | 0 | 0 | 0.33 | 0.17 | 0.16 |
EBIT | -14.87 | -16.94 | -5.82 | -1.65 | -1.62 | -1.27 |
EBIT Margin | -248.65% | - | - | -188.64% | -35.92% | -34.81% |
Revenue as Reported | - | - | - | - | 4.51 | 3.67 |